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Abstract 
Parkinson’s disease(PD) is a metacentric neurodegenerative disorder results with 
accumulation and aggregation of alpha-synculein(α-Syn) (or alpha-synculeinopathy) in 
the substantia nigra in the central nervous system(CNS).Contributory factors include 
pesticide exposure, head injury and agriculture background. PD has been considered to 
be a non-genetic disorder, however around 15% individuals with PD have firstdegree 
relative who has the disease Mutations in genes including SNCA,LRRK2 and 
gluococerebrosidase (GBA) found to be risk factor for sporadic PD. Brain cells could be 
lost due to an abnormal accumulation of the protein alpha-synculein.This insoluble 
protein accumulates inside neurons forming inclusions called Lewy bodies. Other cell 
death mechanisms include proteasomal and lysosomal system dysfunction, but the 
mechanisms are not fully understood. Brain –gut axis(GBA) refers to central nervous 
system(CNS) control of the enteric nervous system(ENS) through vagus nerve 
intervention. PD is characterized by alphasynculeinopathy affecting all levels of the 
brain-gut axis.Both clinical and neuropathological evidences indicate the 
neurodegenerative changes in PD are accompanied by gastrointestinal symptoms that 
may precede or follow the central nervous systemimpairment. Frequent symptoms in 
PD include tremor, rigidity, slowness of movement and difficulty with walking. 
Treatment with L-DOPA(levodopa),with dopamine agonist, medications become less 
effective and produce complications. Research studies recommend new therapeutic 
approach in PD based on modification of the gut microbiota with probiotics, prebiotics, 
or even fecal microbiota transplantation. 
